Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies

The recent emergence of the Omicron BA.1 and BA.2 variants with heavily mutated spike proteins has posed a challenge to the effectiveness of current vaccines and to monoclonal antibody therapy for severe COVID-19. After two immunizations of individuals with no history of previous SARS-CoV-2 infectio...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Hao, Dcosta, Belinda M., Landau, Nathaniel R., Tada, Takuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228817/
https://www.ncbi.nlm.nih.gov/pubmed/35746806
http://dx.doi.org/10.3390/v14061334

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9228817/
https://www.ncbi.nlm.nih.gov/pubmed/35746806
http://dx.doi.org/10.3390/v14061334

Ejemplares similares